OBJECTIVE	We explored the impact of baseline left ventricular hypertrophy ( LVH ) and losartan treatment on renal and cardiovascular ( CV ) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan ( RENAAL ) trial , which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy .\